Chinese expert consensus on immune checkpoint inhibitors for perioperative treatment of advanced gastric cancer (2024 edition)

In recent years, the immunotherapy has changed the treatment pattern of advan-ced gastric cancer. The investigators attempt to identify the efficacy and safety of perioperative immuno-therapy by conducting a series of exploratory and confirmatory clinical studies in patients with locally advanced gastric cancer (LAGC). Preliminary results show that the addition of immunotherapy could improve the pathological remission of patients, but the long‑term survival benefits remain unclear. At present, perioperative immunotherapy has been widely used in patients with LAGC, but there is a lack of unified standards and norms for its indications, target audience, treatment cycle, and related safety management. The Gastric Cancer Professional Committee of China Anti‑Cancer Association organizes multidisciplinary experts in the field of gastric cancer in China to summarize the latest guidelines and research evidence, and formulate the Chinese Expert Consensus on Immune Checkpoint Inhibitors for Perioperative Treatment of Advanced Gastric Cancer (2024 Edition) based on clinical practice and joint discussion. The aims of this consensus are to improve the application of periopera-tive immunotherapy of LAGC for clinicians, especially clinicians in primary hospitals, and to improve the diagnosis and treatment.